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Abstract
Introduction: Young women and girls with anorexia nervosa (AN) suffer from abnormalities in melatonin (MEL) secretion, especially in
the nocturnal phase. This is paralleled by a considerable bone mass loss and abnormalities of bone metabolism. As melatonin has been
implicated in playing a role in inducing osteoporosis and that the effect could be mediated by the RANKL/RANK/OPG system, we decided
to investigate the potential associations between MEL and bone status in girls with AN.
Aim: To evaluate the relationship between MEL, bone metabolism (as assessed by serum levels of bone turnover markers [OC and CTx]),
and OPG and sRANKL in girls with AN.
Material and methods: A total of 57 girls with AN and 13 healthy girls, between 13 and 18 years of age, were enrolled in the study, and we
evaluated BMI, fasting levels of OC, CTx, OPG and sRANKL, and levels of MEL (fasting levels and the levels at 2 a.m., at which time the
secretion of the hormone peaks).
Results: We found a significantly increased mean serum level of MEL at 2 a.m. and an increased amplitude between nocturnal and
morning levels of the hormone in girls with AN. We also showed a considerable suppression of the mean OC and CTx levels and an
increase in serum OPG and RANKL levels paralleled by a significantly reduced OPG/sRANKL ratio. The changes in the MEL levels at
2 a.m. showed a statistically significant negative correlation with levels of the bone markers and a positive correlation with sRANKL. The
changes in the amplitude between the nocturnal and morning levels of MEL showed a negative correlation with CTx levels and the OPG/
/sRANKL ratio.
Conclusions: Our results indicate that the abnormalities of bone metabolism in girls with AN are associated with changes in the nocturnal
levels of MEL with RANKL appearing to play an important role in this mechanism. The increased amplitude between the nocturnal and
morning levels of MEL may adversely affect the bone tissue in girls with AN with the effect most likely resulting from influences on the
OPG/RANKL balance. (Pol J Endocrinol 2010; 61 (1): 117–123)
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Streszczenie
Wstęp: U młodych kobiet i dziewcząt z jadłowstrętem psychicznym (AN, anorexia nervosa) stwierdza się zaburzenia w wydzielaniu mela-
toniny (MEL, melatonin), zwłaszcza w fazie nocnej. Jednocześnie obserwuje się znaczny ubytek masy kostnej i zaburzenia w metabolizmie
tkanki kostnej. Ponieważ istnieją sugestie, że MEL może mieć pewien udział  w indukowaniu osteoporozy, i że efekt ten może być
realizowany za pośrednictwem systemu RANKL/RANK/OPG, postanowiono zbadać ewentualne powiązania między MEL a stanem kość-
ca u dziewcząt z AN. Celem badań była ocena związku między MEL, metabolizmem tkanki kostnej (ocenianym na podstawie oznaczeń
w surowicy krwi markerów obrotu kostnego (OC i CTx) a OPG i sRANKL u dziewcząt z AN.
Materiał i metody: Badaniami objęto 57 dziewcząt z AN i 13 zdrowych w wieku  13–18 lat, u których oceniono BMI oraz stężenia OC, CTx,
OPG i sRANKL na czczo oraz MEL (2-krotnie w ciągu doby: na czczo i o godz. 2.00, odpowiadającej maksimum wydzielania hormonu).
Wyniki: U dziewcząt z AN stwierdzono istotne zwiększenie średniego stężenia MEL w surowicy o godzinie 2.00 oraz wzrost amplitudy
pomiędzy nocnymi i porannymi wartościami hormonu. Wykazano także znaczną supresję średnich stężeń OC i CTx oraz wzrost OPG
i sRANKL w surowicy przy istotnie obniżonej wartości wskaźnika OPG/sRANKL. Zmiany w stężeniach MEL o godzinie 2.00 korelowały
ujemnie, znamiennie statystycznie ze stężeniami badanych markerów kostnych, a dodatnio z sRANKL. Zmiany w wartościach amplitudy
pomiędzy nocnymi i porannymi stężeniami MEL korelowały ujemnie ze stężeniami CTx i wartościami wskaźnika OPG/sRANKL.
Wnioski: Uzyskane wyniki wskazują, że zaburzenia metabolizmu kostnego u dziewcząt z AN są związane ze zmianami stężeń MEL
w godzinach nocnych, a istotną rolę w tym mechanizmie wydaje się odgrywać RANKL. Zwiększenie amplitudy pomiędzy nocnymi
i porannymi stężeniami MEL może niekorzystnie wpływać na tkankę kostną u dziewcząt z AN; efekt ten jest najprawdopodobniej reali-
zowany poprzez wpływ na równowagę OPG/RANKL. (Endokrynol Pol 2010; 61 (1): 117–123)
Słowa kluczowe: melatonina, stan kośćca, jadłowstręt psychiczny, dziewczęta
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Introduction
Osteoporosis is one of the common complications of
anorexia nervosa (AN) [1–4]. Its aetiology is multifacto-
rial, and the multiaxial disturbances of the formation
and release of osteotropic factors, mainly hormones and
possibly also melatonin (MEL), and cytokines may lead
to reduced bone mineral density (BMD) or a lack of the
expected BMD rise during puberty [1–3, 5, 6]. This re-
sults from excessive bone resorption and insufficient
bone formation. In light of the most recent evidence,
the effects of these factors, including MEL, on bone re-
modelling may be mediated by their direct influence
on the receptor activator of nuclear factor-kB ligand/
/receptor activator of nuclear factor-kB/osteoprotegerin
(RANKL/RANK/OPG) system [7–11]. It may also result
from their direct inhibitory effect on the formation of
pro-resorptive cytokines, such as interleukin-1 (IL-1),
interleukin-6 (IL-6), tumour necrosis factor a (TNF-a),
and macrophage colony stimulating factor (M-CSF), and
from their stimulatory effects on the formation of trans-
forming growth factor b (TGF-b) and insulin-like growth
factor 1 (IGF-1), which secondarily modulate the
RANKL/RANK/OPG system [12–14].
RANKL, which is formed in the bone by osteoblasts
and bone marrow stromal cells, is a type II transmem-
brane protein devoid of the signal peptide which sti-
mulates the maturation, activity, and apoptosis of oste-
oclasts. It also affects the cells of the osteoclast cell line
through RANK, which is a type I transmembrane pro-
tein of the TNF receptor superfamily that is only expres-
sed by osteoclasts and its precursors. The stimulation
of RANK triggers the differentiation of pluripotent oste-
oclast precursor cells to mature osteoclasts, reorganisa-
tion of the cytoskeleton, increased resorptive activity
of mature osteoclasts, and the inhibition of apoptosis
[7–11, 13, 14]. Similarly to RANKL, osteoprotegerin is
a receptor protein of the TNF receptor superfamily that
is mainly formed by osteoblasts and bone marrow stro-
mal cells. It is a specific “trap receptor” for RANKL, as
by binding with RANK it makes it prevents it from bin-
ding with RANK, which decreases the pool of active
osteoclasts and limits bone resorption [7–11, 13, 14].
Results of the most recent studies indicate that MEL,
which plays an important role in the regulation of syn-
thesis and release of many osteotropic hormones and
cytokines [15], may also affect the structural bone mo-
delling and/or remodelling and bone mineralisation [16–
–18]. Koyama et al. [19] demonstrated that pharmaco-
logical doses of the hormone inhibit RANKL in vitro
expression and increase OPG expression in MC3T3-E1
mouse osteoblasts, which suggests that MEL may af-
fect bone status by means of OPG and/or RANKL. Stu-
dies on the experimental osteoporosis model [20–23] and
the few studies in perimenopausal women [18, 24–26] in-
dicate that in addition to the sex steroid deficiency that
manifests with age and the changes in the levels of many
well-studied local and systemic factors, MEL deficien-
cy may also play a role in the development of osteopo-
rosis. In light of the above evidence, it may be hypothe-
sised that the abnormalities in MEL secretion seen in
young women [27–31] and girls with AN [32] observed
by some authors could be a contributing factor to bone
loss and that the effect could be mediated by OPG and/
/or RANKL. Several authors have determined OPG in
girls with AN and established, similarly to young wo-
men with AN [33], significantly elevated serum levels
of this cytokine [34]. Only one study determined OPG
and RANKL in adolescent girls with AN, showing
a negatively correlating with RANKL and a positively
correlating with BMD suppression of the OPG/RANK
relation [35]. No studies have been conducted so far that
would investigate the potential relationship between
abnormalities in MEL secretion (especially in the noc-
turnal phase) in girls with AN and bone turnover, in
terms of the role of OPG and/or RANKL.
The aim of our study was to evaluate the relation-
ship between MEL, bone metabolism (as assessed by
serum biochemical markers of bone formation, osteocal-
cin [OC], bone resorption, and C-terminal telopeptide-
a of type I collagen [CTx]) and OPG, and the soluble
RANK ligand (sRANKL) in girls with AN.
Material and methods
The study enrolled 57 girls between 13 and 18 years of
age, hospitalised at the Paediatric Endocrinology Ward of
the Department of Paediatrics in Zabrze, Medical Univer-
sity of Silesia, Poland, diagnosed with AN following a pa-
ediatric examination and a psychiatrist consultation, in
accordance with the ICD-10 and DSM-IV diagnostic crite-
ria. We enrolled patients with primary or secondary ame-
norrhoea at the moment of diagnosis and a BMI equal to
or lower than 17.5 kg/m2. We qualified patients without
serious somatic complications and with normal liver and
kidney function in whom other psychiatric disorders had
been ruled out. None of the patients was taking drugs that
might affect nutritional status or bone metabolism at ba-
seline. We excluded patients with serious somatic compli-
cations (gastrointestinal bleeding, chronic diarrhoea, de-
hydration, peptic ulcer disease, liver, or kidney dysfunc-
tion) and patients requiring medication.
The control group consisted of 13 healthy, regularly
menstruating girls 13 to 18 years of age, with normal
body mass, in whom endocrine and other disorders that
might affect fat or bone metabolism had been ruled out.
All the girls were placed under the same nutritional
conditions throughout the study (the meals were di-
119
Endokrynologia Polska/Polish Journal of Endocrinology 2010; 61 (1)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
spensed at 8 a.m., 1 p.m., and 6 p.m.), showed normal
activity during the day, turned in at 10 p.m. (lights off)
and slept until 6 a.m. (lights on).
We measured height and body mass, evaluated body
proportions based on the physical growth percentile
charts currently applicable in Poland, and calculated BMI.
Blood (5 ml) for determination of MEL, bone mar-
kers, OPG, and sRANKL was always collected under the
same conditions, between 8 and 9 a.m. following 12-hour
fasting (in the case of MEL an additional 3 ml sample
was collected at 2 a.m. under red lighting conditions) and
the centrifuged serum was frozen and stored at –74°C
until analysis. Determinations of MEL were performed
by RIA (DRG, USA), OC by ELISA (DLS Inc., USA), CTx
by Serum CrossLaps ELISA (Nornic Bioscience Diagno-
stics A/D, Denmark), and OPG and RANKL by ELISA
(Biomedica, Poland). The sensitivity, intra-assay error,
and inter-assay error were 1 pg/ml, 7.5% and 9.5% for
MEL, 0.05 nmol/ml, 5.8% and 7.3% for OC, 0.08 nmol/ml,
5.2% and 6.7% for CTx, 0.14 pmol/L, 7.0% and 7.5% for
OPG, and 0.04 pmol/L, 5% and 7% for RANKL.
The results of the anthropometric measurements
and evaluations were subjected to statistical analyses.
In order to demonstrate significant differences betwe-
en the groups of girls we used the t-Student test (for
variables with a normal distribution) or the U Mann-
Whitney test (for variables with a non-normal distribu-
tion). The relationship between BMI, levels of MEL,
bone markers, OPG, sRANKL, and the OPG/sRANKL
ratio in girls with AN were assessed by Pearson’s corre-
lation test (for variables with a normal distribution) or
Spearman’s correlation test (for variables with a non-
normal distribution). The significance level was p £ 0.05.
Results
The mean body mass and BMI values were significan-
tly lower in girls with AN versus controls (39.50 kg v.
52.58 kg and 15.09 kg/m2 v. 19.65 kg/m2, respectively).
Girls with AN showed a significantly higher mean
MEL levels at 2 am compared to controls (448.10 pmol/L
v. 417.45 pmol/L) and a significantly greater difference
between the nocturnal and morning levels of the hor-
mone (411.91 pmol/L v. 351.19 pmol/L). Patients with
AN had a significant suppression of bone formation
markers (OC, 0.96 nmol/ml v. 3.19 nmol/ml) and bone
resorption markers (CTx, 6.90 nmol/L v. 7.85 nmol/L) (Fi-
gure 1). We also observed a considerable increase in
OPG and sRANKL levels in patients with AN compared
to controls (3.97 pmol/L v. 3.59 pmol/L and 0.499 pmol/L
v. 0.275 pmol/L) paralleled by a significantly reduced
OPG/sRANKL ratio (10.24 v. 14.28) (Table I).
Patients with AN showed a significantly positive
correlation of BMI with the levels of OC and CTx and
with the value of the OPG/sRANKL ratio, and a negati-
ve correlation with OPG and sRANKL. OPG levels sho-
wed a significant positive correlation with sRANKL and
a negative correlation with the OPG/sRANKL ratio.
sRANKL levels showed a significant negative correla-
tion with OC, CTx, and OPG/sRANKL. We also found
a positive significant correlation of OC with OPG/
/sRANKL. Girls with AN also showed a significant ne-
gative correlation of MEL at 2 a.m. with the bone mar-
kers and a positive correlation with sRANKL, and
a negative significant correlation of amplitude betwe-
en nocturnal and morning MEL levels with CTx and
OPG/sRANKL ratio (Table II).
Discussion
Anorexia nervosa is a serious psychosomatic disorder
with onset mainly during puberty, in which patients
(generally girls and young women), by imposing upon
Table I. Age, height, body mass, body mass index (BMI),
melatonin (MEL), osteocalcin (OC), c-terminal telopeptide of
type I collagen (CTx), osteoprotegerin (OPG), and receptor
activator of nuclear-kB ligand (sRANKL) levels as well as
values of OPG/sRANKL index in girls with anorexia nervosa
and girls in the control group
Tabela I. Wiek, wzrost, masa ciała, wskaźnik masy ciała
(BMI) oraz stężenia melatoniny (MEL), osteokalcyny (OC),
c-końcowego usieciowanego telopeptydu łańcucha a1
kolagenu typu I (CTx), osteoprotegeryny (OPG), ligandu
receptora aktywatora czynnika jądrowego-kB (sRANKL),
a także wartość wskaźnika OPG/sRANKL u dziewcząt
z jadłowstrętem psychicznym i w grupie kontrolnej
Variables Groups
Anorexia Control
nervosa  (n = 13)
 (n = 57)
Age (years) 15.46±1.59 15.85±1.95
Height [m]  1.62±0.07 1.63±0.08
Weight [kg] 39.50±6.29* 52.58±6.68
BMI [kg/m2] 15.09±1.96* 19.65±1.53
MEL [pmol/L]
na czczo 59.34±50.26 66.26±42.60
2.00 a.m. 488.10±76.19^ 417.45±50.26
D [pmol/L] 411.91±59.13^ 351.19±60.32
OC [nmol/ml]  0.96±0.66* 3.19±1.59
CTx [nmol/L]   6.90±1.00^ 7.85±0.90
OPG [pmol/L]  3.97±0.50#  3.59±0.70
sRANKL [pmol/L] 0.499±0.23* 0.275±0.118
OPG/sRANKL 10.24±3.92# 14.28±3.99
#p £ 0.05; ^p £ 0.01; *p £ 0.001 — significant difference compared
to control group
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themselves a restrictive diet and other activities (such
as increased physical activity, vomiting, laxation), elicit
weight loss [2, 4]. This leads to abnormalities in the forma-
tion and release of various hormones, mainly hormones
of the pituitary-ovarian, pituitary-adrenal, pituitary-thy-
roid and somatotropin axes, calciotropic hormones, adi-
pose tissue hormones [3, 5, 6, 34, 36–38], and MEL [27–32].
These abnormalities may lead to a BMD decrease or
a loss of the expected BMD rise associated with the pre-
dominance of bone resorption over bone formation pro-
cesses during physical growth [1, 3, 5, 36]. Patients with
AN achieve lower values of peak bone mass and are
therefore at risk of osteoporosis in adult life [3]. Deter-
mination of the bone formation and bone resorption
markers in women with AN point to a reduced rate of
bone formation (low levels of OC and the bone fraction
of serum alkaline phosphatase) and increased bone re-
sorption (elevated serum CTx and NTx and elevated
urinary deoxypyridinoline) [39–42].
Such a bone metabolism status associated with incre-
ased bone resorption and reduced bone formation contri-
butes to intensive bone loss. Maugars et al. [43] observed
borderline high serum OC levels paralleled by elevated
urinary hydroxyproline in patients with AN, which, in
contrast to the previous studies, suggests a high bone tur-
nover in this group of patients. Similarly, Owada et al. [33]
showed elevated serum levels of OC and bone fraction
of serum alkaline phosphatase and an increased urina-
ry level of CTx in young women with AN which was
paralleled by elevated OPG and unchanged RANKL.
In girls with AN, on the other hand, bone marker
suppression generally correlating with BMI and BMD
has been observed, which suggests reduced bone tur-
nover [36, 44–48] and increased serum levels of OPG
[34]. Although some authors have observed unchanged
or increased levels of bone resorption markers [37, 38,
44, 49], OPG levels showed a negative correlation with
BMI, body fat, and BMD [34]. Our study has shown
a significant reduction in the mean serum levels of bone
markers, both OC and CTx, more pronounced in the
case of OC, paralleled by elevated OPG and sRANKL
and significantly reduced OPG/sRANKL. We also fo-
und a significant positive correlation of BMI with OC,
CTx, and OPG/sRANKL and a negative correlation with
OPG and sRANKL. The confirmed increased OPG le-
vels in girls with AN seems to be compensatory in na-
ture relative to the increased bone resorption [34], as
confirmed by the positive correlation between OPG and
sRANKL and the negative correlation with OPG/
/sRANKL we observed. In addition, sRANKL levels sho-
wed a significant negative correlation with the bone
markers we investigated and the OPG/sRANKL ratio.
We further observed a significant positive correlation
between OC and OPG/sRANKL. As we did in our stu-
dy, Munoz-Calvo et al. [35] demonstrated a reduction
in the OPG/sRANKL ratio in girls with AN that was si-
gnificant and correlated with increased RANKL levels.
Serum OPG levels were, on the other hand, only sligh-
tly elevated. A high positive correlation between the
OPG/RANKL ratio and BMD was also found. The au-
thors concluded that the reduction in the OPG/RANKL
ratio in girls with AN partly explained the increases in
bone loss observed in this group of patients. Other au-
thors showed a significant increase in OPG levels and
a significant negative correlation between OPG and
BMD in girls with AN [34]. Others still observed eleva-
Table II. Correlation between melatonin (MEL), osteocalcin (OC), c-terminal telopeptide of type I collagen (CTx), osteoprotegerin
(OPG), receptor activator of nuclear-kB ligand (sRANKL) levels and body mass index (BMI) and OPG/sRANKL values in girls
with anorexia nervosa (n = 57)
Tabela II. Korelacja między stężeniami melatoniny (MEL), osteokalcyny (OC), c-końcowego usieciowanego telopeptydu
łańcucha a 1 kolagenu typu I (CTx), osteoprotegeryny (OPG),  ligandu receptora aktywatora czynnika jądrowego-kB (sRANKL)
i wskaźnikami masy ciała (BMI) i OPG/sRANKL u dziewcząt z jadłowstrętem psychicznym (n = 57)
Variables OC [nmol/ml] CTx [nmol/L] OPG [pmol/L] sRANKL [pmol/L] OPG/sRANKL
MEL [pmol/L]
na czczo  0.183 0.161 –0.122 –0.168 0.128
2.00 a.m.   –0.364^ –0.659* 0.234    0.790* –0.219
D –0.150 –0.505* 0.211 0.235 –0.294#
BMI [kg/m2]    0.254# 0.346^ –0.259#   –0.347^ 0.267#
OPG [pmol/L] –0.110 –0.143 –   0.258# –0.402*
sRANKL [pmol/L]   –0.298# –0.380^ 0.258* – –0.741*
OPG/sRANKL    0.323^ 0.228 –0.402* –0.742* –
#p £ 0.05; ^p £ 0.01; *p £ 0.001 –— statistically significant values of correlation coefficients
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ted bone marker levels (OC and CTx) paralleled by in-
creased OPG levels in young women with AN [33],
while Khal et al. [50] found elevated OC and CTx in the
serum paralleled by reduced OPG levels in young wo-
men with AN suffering from severe depression. These
equivocal results may stem from the fact that the stu-
dies were not always conducted under similar condi-
tions in terms of height, pubescence stage and bone
modelling [35], and the duration of the disease in gro-
ups of adolescent girls with AN [47]. The differences in
serum levels of OPG may also be related to the fact that
OPG is not only formed by osteoblasts and bone mar-
row stromal cells, as OPG mRNA transcripts have also
been found in lymphoid cells, kidneys, liver, thyroid
gland, and many foetal tissues [51].
The bone turnover abnormalities that correlated
with OPG and sRANKL and with the OPG/sRANKL
ratio were accompanied by a significant increase in the
MEL levels at 2 p.m., corresponding to the peak secre-
tion of the hormone, and by a significant increase in
the amplitude between the nocturnal and morning le-
vels. These results suggest the possible involvement of
MEL in the mechanism that leads to reduced BMD
manifesting in girls with AN and resulting from bone
turnover abnormalities. Studies conducted in recent
years have shown that MEL, a hormone mainly syn-
thesised by the pineal gland and playing an important
role in the regulation of the synthesis and release of
hormones [15], whose concentrations change significan-
tly in patients with AN [3, 6], may affect the bone [16–
–18]. Lighting conditions, removal of the pineal gland,
and long-term administration of MEL have been shown
to modify circadian bone metabolism in rats [23, 52, 53].
Studies in ovariectomised rats [20–23] and the few stu-
dies in postmenopausal women [24–26] have shown
that MEL deficiency may contribute to the induction of
postmenopausal osteoporosis. On the other hand, ad-
ministration of MEL to gelded female and male rats le-
ads to increased BMD and suppression of bone mar-
kers, especially bone resorption markers [20, 21, 23, 54].
It has also been shown that excessive formation of the
hormone during the day, as seen in obesity, may bene-
ficially affect the bone after the menopause [17, 18].
Some authors, based on animal and human studies (in
vivo and in vitro), suggest that MEL may directly and/or
indirectly affect both the formation and resorption of
bone [16–18]. Sex and adrenal steroids, calciotropic hor-
mones, somatotropic axis hormones, thyroid axis hor-
mones, and prostaglandin E2 seem to play an impor-
tant role in the indirect effect of MEL on bone cells [52,
53]. Other authors, based on in vitro and in vivo studies
in mice and rabbits, have shown that MEL mainly af-
fects bone resorption and does so indirectly rather than
directly [19]. MEL at doses of 5–500 µM has been shown
to reduce, in a dose-dependent manner, RANKL mRNA
expression in the MC3T3-E1 osteoblast cell line of mice,
and to increase OPG mRNA expression. Hence the hy-
pothesis that MEL, by affecting OPG and/or RANKL
expression in osteoblasts and bone marrow stromal cells,
may regulate the size of the active osteoclast pool and
therefore bone resorption [19]. The few human studies,
mainly in obese postmenopausal women, seem to cor-
roborate the above concept [17–18].
The studies conducted in patients with AN so far
have mainly focused on evaluating the relationships
between MEL and body mass composition and BMI,
and have been conducted mostly in adult patients.
However, results of these studies are equivocal. Torto-
sa et al. [29] found significant increases in the mean
24-hour and nocturnal levels of MEL in young women
with AN without any changes in the acrophase. Simi-
larly, other researchers [27, 28, 30, 31] observed a mar-
ked increase in MEL levels in the nocturnal phase wi-
thout disturbances in the circadian rhythm, while Ken-
nedy et al. [55, 56] found a significant reduction in noc-
turnal MEL levels, but only in women with AN suffering
from depression. Other researchers [57–59], on the other
hand, observed no significant changes in circadian le-
vels of MEL in patients with AN. The discrepancies may
be related to the fact that some of the AN patients were
also suffering from depression, hence the reduced MEL
values. Dalery et al. [32] showed higher MEL levels at
time points corresponding to peak secretion in adole-
scents with AN than in depressed girls, although the
studies by these authors did not include a group of he-
althy girls. In our study we found a significant increase
in the mean serum levels of MEL at 2 a.m. and an incre-
ase in the amplitude between the nocturnal and mor-
ning levels of the hormone compared to healthy girls.
We did not show any significant differences in the mor-
ning values of MEL between the girls with AN and the
healthy girls. Because no studies investigating the rela-
tionship between MEL and bone metabolism, taking
into account the involvement of the cytokines of the
RANKL/RANK/OPG system, had been conducted at
that time, we performed such a study. We showed that
the changes in MEL levels at 2 a.m. in girls with AN
showed a negative and statistically significant correla-
tion with bone marker levels and a positive correlation
with sRANKL, which suggests that MEL may modula-
te bone turnover through RANKL. This evidence sug-
gests that the abnormalities in MEL secretion in the
nocturnal phase could play a role in the mechanism le-
ading to BMD reduction in girls with AN. This is sup-
ported by the fact that the amplitude values between
the nocturnal and morning MEL levels showed a signi-
ficant negative correlation with CTx and the OPG/
/sRANKL ratio.
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Conclusions
Our results indicate that the abnormalities of bone me-
tabolism in girls with AN are associated with changes
in the nocturnal levels of MEL, with RANKL appearing
to play an important role in this mechanism. The incre-
ased amplitude between the nocturnal and morning
levels of MEL may adversely affect the bone tissue in
girls with AN, with the effect most likely resulting from
influences on the OPG/RANKL balance.
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